Market capitalization | DKK35.46b |
Enterprise Value | DKK35.41b |
P/E (TTM) P/E ratio | 45.16 |
EV/FCF (TTM) EV/FCF | 42.77 |
EV/Sales (TTM) EV/Sales | 6.58 |
P/S ratio (TTM) P/S ratio | 6.59 |
P/B ratio (TTM) P/B ratio | 6.97 |
Revenue growth (TTM) Revenue growth | 13.85% |
Revenue (TTM) Revenue | DKK5.38b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
7 Analysts have issued a Alkello A S forecast:
7 Analysts have issued a Alkello A S forecast:
Sep '24 |
+/-
%
|
||
Revenue | 5,383 5,383 |
14%
14%
|
|
Gross Profit | 3,442 3,442 |
16%
16%
|
|
EBITDA | 1,336 1,336 |
57%
57%
|
EBIT (Operating Income) EBIT | 1,076 1,076 |
77%
77%
|
Net Profit | 785 785 |
85%
85%
|
In millions DKK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. It also manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark.
Head office | Denmark |
CEO | Peter Halling |
Employees | 2,824 |
Founded | 1923 |
Website | www.alk.net |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.